Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
67.3(c) 65.1(c) 66.64(c) 66.78(c) 65.83(c) Last
483 907 901 077 323 925 313 925 165 408 Volume
-5.22% -3.27% +2.37% +0.21% -1.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 75,7 M - -
Net income 2021 -211 M - -
Net cash position 2021 689 M - -
P/E ratio 2021 -33,4x
Yield 2021 -
Sales 2022 199 M - -
Net income 2022 -118 M - -
Net cash position 2022 530 M - -
P/E ratio 2022 -66,8x
Yield 2022 -
Capitalization 5 066 M 5 066 M -
EV / Sales 2021 57,9x
EV / Sales 2022 22,8x
Nbr of Employees 228
Free-Float 98,7%
More Financials
Company
I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. 
Sector
Pharmaceuticals
Calendar
10/26Presentation
More about the company
Ratings of I-Mab
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about I-MAB
10/15I MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PU
10/13I MAB : Completes Patient Enrollment in Phase 3 Study of Multiple Myeloma Therapy
MT
10/13I-MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PR
10/13I-Mab Advances Late-Stage Development of Its Differentiated CD38 Antibody Felzartamab i..
CI
10/05I-MAB : and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at th..
PR
10/05I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at t..
CI
10/04I MAB : Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzopa..
PU
10/01I-MAB : Announces Upcoming Participation at October Conferences
PR
09/30I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzop..
CI
09/29I MAB : Exploring Partnership, Stake Sale to Major Drugmakers
MT
09/28I-Mab Secures Approval to Conduct Phase 2 Trial of Enoblituzumab Combo Therapy for Soli..
MT
09/28I-MAB : Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial..
PR
09/28I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Tria..
CI
09/20I-MAB(NASDAQGM : IMAB) added to FTSE All-World Index
CI
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
More news
News in other languages on I-MAB
09/29I-Mab étudie la possibilité d'un partenariat ou d'une cession de parts à de grands fabr..
08/31La perte d'I-Mab H1 se creuse
More news
Analyst Recommendations on I-MAB
More recommendations
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | IMAB | US44975P1030 | MarketScreener
Technical analysis trends I-MAB
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 65,83 $
Average target price 95,07 $
Spread / Average Target 44,4%
EPS Revisions
Managers and Directors
Hua Qiong Shen Chief Executive Officer & Director
Zheru Zhang President & Director
Jielun Zhu Chief Financial Officer & Director
Jing Wu Zang Chairman
Lili Qian Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
I-MAB39.62%5 066
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657